Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders

Abstract

Pharmacological and anatomical evidence suggests that abnormal glutamate neurotransmission may be associated with the pathophysiology of schizophrenia and mood disorders. Medial temporal lobe structural alterations have been implicated in schizophrenia and to a lesser extent in mood disorders. To comprehensively examine the ionotropic glutamate receptors in these illnesses, we used in situ hybridization to determine transcript expression of N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and kainate receptor subunits in the medial temporal lobe of subjects with schizophrenia, bipolar disorder (BD), or major depression (MDD). We used receptor autoradiography to assess changes in glutamate receptor binding in the same subjects. Our results indicate that there are region-and disorder-specific abnormalities in the expression of ionotropic glutamate receptor subunits in schizophrenia and mood disorders. We did not find any changes in transcript expression in the hippocampus. In the entorhinal cortex, most changes in glutamate receptor expression were associated with BD, with decreased GluR2, GluR3, and GluR6 mRNA expression. In the perirhinal cortex we detected decreased expression of GluR5 in all three diagnoses, of GluR1, GluR3, NR2B in both BD and MDD, and decreased NR1 and NR2A in BD and MDD, respectively. Receptor binding showed NMDA receptor subsites particularly affected in the hippocampus, where MK801 binding was reduced in schizophrenia and BD, and MDL105,519 and CGP39653 binding were increased in BD and MDD, respectively. In the hippocampus AMPA and kainate binding were not changed. We found no changes in the entorhinal and perirhinal cortices. These data suggest that glutamate receptor expression is altered in the medial temporal lobe in schizophrenia and the mood disorders. We propose that disturbances in glutamate-mediated synaptic transmission in the medial temporal lobe are important factors in the pathophysiology of these severe psychiatric illnesses.

New hypothesis and treatment targets of depression: an integrated view of key findings

“…and apoptosis or degeneration [54] . In fact, recent research has revealed that the levels of AMPARs and NMDARs decrease in both depressed patients and depressive animal models after long-term stress, and this decline may be attributed to the over-activation of GRs and degradation of glutamate receptors [55,56] . (Fig.…”

Expression of Transcripts for Myelin Related Genes in Postmortem Brain from Cocaine Abusers

“…[S 35 ]-labeled sense and antisense RNA probes were synthesized using SP6 and T7 RNA polymerase as previously described [45]. Briefly, 100 μCi dried [S 35 ]UTP was mixed with 1.5 μg linearized plasmid, 2 μl transcription buffer (5×; Promega), 3 mM NTPs (CTP, ATP, GTP), 1 μl 0.1 M dithiothreitol (DTT), 0.5 μl RNAse inhibitor and 25 units SP6 or T7 (Promega) in a total volume of 10 μl and incubated at 37°C for 2 h. Following incubation, probes were DNAse treated (1 μl DNAse1 for 15 min at room temperature (RT)), diluted in G50-50 buffer (100 mM Tris-HCl, 12.5 mM EDTA, 150 mM NaCl, and 0.2% sodium dodecyl sulfate, pH 7.5) and purified using micro Bio-Spin P-30 chromatography columns (Bio-Rad).…”

Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?

“…[124][125][126] This is of particular interest to the AA hypothesis as NMDA-mediated receptor stimulation increases the intracellular level of calcium, an activator of cPLA 2 . 127 Basselin and co-workers 40,128 found that acute administration of subconvulsant Collectively, these studies suggest that lithium alters AA signaling via PLA 2 as coupled to a variety of neuroreceptor subtypes (NMDA, serotonergic, dopaminergic and cholinergic) and are consistent with lithiumnormalizing neurotransmission imbalances that may account for the symptoms of bipolar disorder.…”